Nippon India Pharma Fund - Growth
Empty
1–7 yearsInvestment Horizon
HNI,MATarget Segments
Empty
Performance and Risk Analysis
Historical returns, volatility patterns, and how this fund has performed relative to its benchmark.
Risk Profile
Standard Deviation18.0%
Sharpe Ratio0.57
Beta0.91
Strategy Details
A closer look at the investment thesis, portfolio construction, and current holdings.
Portfolio Holdings Overview
SectoralAllocation
Geographic Allocation
Domestic100%
Top Stock Holdings
CompanySectorAllocation
Sun Pharmaceuticals Industries LtdServices12.57%
Divi's Laboratories LtdServices9.49%
Lupin LtdServices5.82%
Cipla LtdServices5.62%
Dr Reddy's Laboratories LtdServices5.49%
Apollo Hospitals Enterprise LtdServices5.34%
Medplus Health Services LtdServices4.20%
GlaxoSmithKline Pharmaceuticals LtdServices3.73%
Vijaya Diagnostic Centre LtdServices3.24%
Narayana Hrudayalaya LtdServices2.94%
Operational & Regulatory Details
What it costs to invest, transaction mechanics, and regulatory disclosures you should know.
Costs and Fees
Total Expense Ratio (TER)1.8%
Exit Load1
Regulatory & Tax Information
INF204K01968
ISINDailyDealing Frequency
BSE Healthcare PRBenchmark
LTCG | >1Year 12.5%% on gain above 1.25 Lakh
STCG | <1Year 20%%
Tax Implications (India)